WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced robust demand-led growth for its molluscum contagiosum treatment, YCANTH®, during the first quarter of 2025. The company reported a 16.7% sequential increase in dispensed applicator units, rising from 8,654 units in the fourth quarter of 2024 to 10,102 units in the first quarter.
“This strong performance reflects the positive impact of our recent commercial restructuring,” said Jayson Rieger, PhD, MBA, President and CEO of Verrica. He noted that normalized distribution inventory and growing prescriber demand were key contributors to the quarter’s success.
Dr. Rieger emphasized Verrica’s strengthened market access and the efforts of its focused commercial team, adding that these elements have paved the way for sustained revenue growth. “We believe YCANTH is now positioned to become the standard of care for molluscum contagiosum treatment,” he stated.
With the first-quarter milestones reflecting rising demand and improved operational alignment, Verrica is poised for continued growth in 2025 and beyond.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.